<PAGE> 1
---------------------------
OMB APPROVAL
---------------------------
- -------- OMB Number: 3235-0104
FORM 3 Expires: September 30, 1998
- -------- Estimated average burden
hours per response .... 0.5
---------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a)
of the Public Utility Holding Company Act of 1935 or Section 30(f)
of the Investment Company Act of 1940
<TABLE>
<S> <C> <C> <C>
- -----------------------------------------------------------------------------------------------------------------------------------
1. Name and Address of Reporting Person 2. Date of Event Requiring 4. Issuer Name and Ticker or 6. If Amendment, Date
S.R. One, Limited Statement Trading Symbol of Original
- ---------------------------------------- (Month/Day/Year) Ribi Immunochem Research, Inc. (RIBI) (Month/Day/Year)
(Last) (First) (Middle) 12/31/96 ------------------------------------
Bay Colony Executive Park ---------------------------- 5. Relationship of Reporting 7. Individual or
565 E. Swedesford Road 3. IRS or Social Security Person to Issuer Joint/Group
- ---------------------------------------- Number of Reporting (Check all applicable) Filing Check
Suite 315 Person (Voluntary) ----- Director -X- 10% Owner Applicable Line)
Radnor PA 19087 23-1729901 ----- Officer ----- Other (specify -- Form filed by one
- -------------------------------------- ---------------------------- (give title below) below) Reporting Person
(City) (State) (Zip) X Form filed by
more than One
Reporting Person
---------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
TABLE 1 -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED
- -----------------------------------------------------------------------------------------------------------------------------------
1. Title of Security 2. Amount of Securities 3. Ownership Form: 4. Nature of Indirect
(Instr. 4) Beneficially Owned Direct (D) or Beneficial
(Instr. 4) Indirect (I) Ownership (Instr. 5)
(Instr. 5)
Common Stock 750,608 D
- -----------------------------------------------------------------------------------------------------------------------------------
Common Stock 1,103,448 I by Corporation
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Over)
(Print or Type Responses) SEC 1473 (7/96)
</TABLE>
<PAGE> 2
<TABLE>
<CAPTION>
FORM 3 (CONTINUED) TABLE II -- DERIVATIVE SECURITIES BENEFICIALLY OWNED
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
<S> <C> <C> <C> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative Security 2. Date 3. Title and Amount of 4. Conver- 5. Owner- 6. Nature of Indirect
(Instr. 4) Exercisable and Securities Underlying sion or ship Beneficial Ownership
Expiration Date Derivative Security Exercise Form of (Instr. 5)
(Month/Day/ (Instr. 4) Price of Deriv-
Year) Deri- ative
vative Security:
Security Direct
------------------------------------------------- (D) or
Date Expira- Amount or Indirect (I)
Exercis- tion Title Number (Instr. 5)
able Date of Shares
Non-Qualified Stock Option
(right to buy) 12/31/96 12/31/98 Common Stock 551,724 (2) I by Corporation (1)
- ------------------------------------------------------------------------------------------------------------------------------------
Warrant to Purchase Common
Shares 12/31/96 12/31/99 Common Stock 500,000 $5.0000 I by Corporation (1)
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
Explanation of Responses:
(1) Owned of record by SmithKline Beecham Biologicals Manufacturing S.A., an affiliate of Reporting Person, both of which are under
common control as subsidiaries of SmithKline Beecham Corporation.
(2) The purchase price is defined as the average of the mean of the high and low prices for the Common Shares as reported on the
NASDAQ National Market tier of the NASDAQ Stock Market for each of the five (5) consecutive trading days ending two (2) trading days
prior to December 31, 1998, the expiration date for Stock Options.
**Intentional misstatements or omissions of facts constitute Federal Criminal ------------------------------- -------------
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **Signature of Reporting Person Date
Note. File three copies of this Form, one of which must be manually signed. Page 2
If space provided is insufficient, See Instruction 6 for procedure. SEC 1473 (7/96)
</TABLE>
